Business
DiaMedica Therapeutics to Participate in Upcoming Investor Conferences in May
MINNEAPOLIS, May 08, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025.
About this update from Diamedica Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":631,"url":"https://media.zenfs.com/en/business-wire.com/9822e5a6bcf59dff567a07fe880c34e9"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/_R2zsrs1Jkq9UV_BBKpHCQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/9822e5a6bcf59dff567a07fe880c34e9","width":960,"height":303},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/rprFK5FlyCwvXU0p1ssJmg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/9822e5a6bcf59dff567a07fe880c34e9","width":1200,"height":379}},"lazy":false},{"type":"text","content":"MINNEAPOLIS, May 08, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, announced today that the Company will participate in upcoming investor conferences in May 2025.","length":295,"tagName":"p"},{"type":"text","content":"2025 RBC Capital Markets Global Healthcare ConferenceTuesday, May 20th – Wednesday, May 21st, 2025, in New York City, New York. Management will be available for one-on-one meetings throughout the conference.","length":208,"tagName":"p"},{"type":"text","content":"H.C. Wainwright 3rd Annual BioConnect ConferenceTuesday, May 20th, 2025, in New York City, New York. Management will participate in a fireside chat at 3:30 PM ET, which will be available via webcast at https://journey.ct.events/view/cb8be4c8-bb67-420a-b0a3-cf76483d9ff3. A replay will also be posted in the Investor Relations section of the Company’s website at www.diamedica.com.","length":381,"tagName":"p"},{"type":"text","content":"22nd Annual Craig-Hallum Institutional Investor ConferenceWednesday, May 28, 2025 - Minneapolis, Minnesota. Management will be available for one-on-one meetings throughout the day.","length":181,"tagName":"p"},{"type":"text","content":"About DiaMedica Therapeutics Inc.","length":33,"tagName":"p"},{"type":"text","content":"DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from preeclampsia and acute ischemic stroke. DiaMedica’s lead candidate, DM199, is the first pharmaceutically active recombin...